Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Novartis | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Novartis

Sales growth offsets Diovan patent expiry

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Novartis
 
4Q Revenues: $14.8 billion (flat)

4Q Earnings: $2.1 billion (+72%)

YTD Revenues: $56.7 billion (-3%)

YTD Earnings: $9.6 billion (+4%)

Comments: Pharmaceutical sales were flat at $8.3 billion in the quarter. Products launched since 2007 generated $3.1 billion or 38% of sales, up 26%, offsetting the loss of exclusivity for Diovan HCT in the U.S. Alcon sales were up 6% to $2.6 billion, with the Surgical franchise up 8%, Ophthalmic Pharmaceuticals up 5%, and Vision Care up 4%. Sandoz sales grew 4% to $2.4 billion, with Fougera contributing 7% of the growth from four months of sales. Vaccines and Diagnostics sales of were $628 million, down 6%. Consumer Health, which includes OTC and Animal Health, declined 11% to $961 million, impacted by the continuing absence of shipments from the Lincoln, NE manufacturing site. Charges in 2011 included $1.0 billion, primarily $0.9 billion related to Tekturna/Rasilez.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters